Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSX NASDAQ:EUDA NASDAQ:SERA NASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$0.32+7.5%$0.32$0.17▼$2.04$43.09M0.972.46 million shs1.22 million shsEUDAEUDA Health$3.18-5.1%$3.63$2.92▼$6.30$124.47M-0.0484,007 shs108,952 shsSERASera Prognostics$2.66-2.2%$2.12$1.37▼$9.13$102.47M0.99180,045 shs90,715 shsXGNExagen$6.83-1.7%$6.73$1.78▼$7.95$148.04M1.58138,494 shs151,079 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix+7.52%+14.95%+9.11%-44.54%-80.49%EUDAEUDA Health-5.07%-9.66%-5.36%-12.88%-15.87%SERASera Prognostics-2.21%+8.57%+77.33%-14.47%-49.72%XGNExagen-1.73%-2.01%-4.74%+61.47%+261.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDSXBiodesix3.3742 of 5 stars4.44.00.00.00.02.50.6EUDAEUDA HealthN/AN/AN/AN/AN/AN/AN/AN/ASERASera Prognostics0.6329 of 5 stars0.04.00.00.00.62.50.0XGNExagen2.964 of 5 stars1.53.00.04.50.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.80Moderate Buy$1.75453.62% UpsideEUDAEUDA Health 4.00Strong BuyN/AN/ASERASera Prognostics 0.00N/AN/AN/AXGNExagen 3.00Buy$7.509.81% UpsideCurrent Analyst Ratings BreakdownLatest BDSX, XGN, EUDA, and SERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025BDSXBiodesixScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$3.00 ➝ $2.005/15/2025XGNExagenUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025XGNExagenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.005/14/2025BDSXBiodesixLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $2.005/14/2025BDSXBiodesixCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.00 ➝ $1.505/14/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $1.505/14/2025BDSXBiodesixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform5/13/2025XGNExagenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/7/2025XGNExagenBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/29/2025BDSXBiodesixCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$3.50 ➝ $2.50(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$71.32M0.65N/AN/A$0.14 per share2.26EUDAEUDA Health$4.01M29.47N/AN/A($0.07) per share-45.43SERASera Prognostics$80K1,252.53N/AN/A$1.40 per share1.90XGNExagen$55.64M2.61N/AN/A$0.54 per share12.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$42.93M-$0.29N/AN/AN/A-54.28%-167.28%-39.96%8/6/2025 (Estimated)EUDAEUDA Health-$15.36MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)SERASera Prognostics-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)XGNExagen-$15.11M-$0.84N/AN/AN/A-27.34%-133.69%-34.87%8/4/2025 (Estimated)Latest BDSX, XGN, EUDA, and SERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025BDSXBiodesix-$0.07N/AN/AN/A$18.47 millionN/A8/6/2025Q2 2025SERASera Prognostics-$0.21N/AN/AN/AN/AN/A8/4/2025Q2 2025XGNExagen-$0.18N/AN/AN/A$16.25 millionN/A7/29/2025N/AEUDAEUDA Health-$0.02N/AN/AN/AN/AN/A5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million5/13/2025Q1 2025BDSXBiodesix-$0.08-$0.08N/A-$0.08$19.50 million$17.96 million5/12/2025Q1 2025XGNExagen-$0.20-$0.20N/A-$0.20$14.55 million$15.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/AEUDAEUDA HealthN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix3.322.222.22EUDAEUDA HealthN/A0.180.15SERASera PrognosticsN/A2.022.02XGNExagen2.872.322.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%EUDAEUDA Health4.35%SERASera Prognostics54.64%XGNExagen75.25%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix30.10%EUDAEUDA HealthN/ASERASera Prognostics13.50%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix220146.56 million102.45 millionOptionableEUDAEUDA Health237.16 millionN/ANot OptionableSERASera Prognostics12037.67 million32.59 millionOptionableXGNExagen22021.30 million18.62 millionOptionableBDSX, XGN, EUDA, and SERA HeadlinesRecent News About These CompaniesExagen Insider Ups Holding During YearJune 29, 2025 | finance.yahoo.com2025-06-23 | Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics | NDAQ:XGN | Press Release - StockhouseJune 24, 2025 | stockhouse.comMichael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune DiagnosticsJune 23, 2025 | globenewswire.comExagen announces resale of up to 1.15M sharesJune 20, 2025 | msn.comCantor Fitzgerald Estimates Exagen FY2026 EarningsJune 13, 2025 | marketbeat.comExagen Inc. Holds 2025 Annual Stockholder MeetingJune 11, 2025 | tipranks.comExagen Inc. (NASDAQ:XGN) Q1 2025 Earnings Call TranscriptMay 11, 2025 | insidermonkey.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional SharesMay 9, 2025 | finance.yahoo.comExagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional SharesMay 9, 2025 | globenewswire.comExagen Inc. Prices Public Offering of Common StockMay 8, 2025 | globenewswire.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comKeyBanc maintains Exagen stock at Sector WeightMay 7, 2025 | investing.comExagen Inc. Announces Proposed Public Offering of Common StockMay 7, 2025 | globenewswire.comEarnings call transcript: Exagen Inc. Q1 2025 revenue beats forecasts, stock dipsMay 6, 2025 | uk.investing.comExagen Inc. Reports Record Revenue Amid Strategic GrowthMay 5, 2025 | tipranks.comExagen Inc. Earnings Call Highlights Record GrowthMay 5, 2025 | tipranks.comExagen Inc. (XGN) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comExagen Inc. (XGN) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2025 | zacks.comExagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing VolumeMay 5, 2025 | globenewswire.comExagen Inc (XGN) Q1 2025 Earnings Report Preview: What To ExpectMay 3, 2025 | finance.yahoo.comPerceptive Advisors Enters $75MM Term Loan Facility with ExagenApril 29, 2025 | abladvisor.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDSX, XGN, EUDA, and SERA Company DescriptionsBiodesix NASDAQ:BDSX$0.32 +0.02 (+7.52%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$0.33 +0.01 (+4.08%) As of 04:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.EUDA Health NASDAQ:EUDA$3.18 -0.17 (-5.07%) Closing price 07/9/2025 03:59 PM EasternExtended Trading$3.10 -0.08 (-2.52%) As of 07/9/2025 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.Sera Prognostics NASDAQ:SERA$2.66 -0.06 (-2.21%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$2.64 -0.02 (-0.56%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Exagen NASDAQ:XGN$6.83 -0.12 (-1.73%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$7.00 +0.17 (+2.49%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Why Marvell Could Be the Smartest AI Bet Under $80 Autodesk Stock Ready to Rip? Q3 May Be the Turning Point Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Palantir’s Revenue Surge to $1B: Growth vs. Valuation Chime Financial: Analysts Ring In—And It’s a Buy Is Fortinet Ready to Break Out After Months of Consolidation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
